CYP2D6 genotype and psychotropic drug-induced adverse effects

Periodicum Biologorum

Volumn 103, Issue 4, 2001, Pages 309-314

  Božina, Nada ^a   Tramišak, Inja ^a   Medved, Vesna ^a   Mihaljević Peleš, Ana ^a   Granić, Paula ^a   Stavljenić Rukavina, Ana ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 2D6; DEBRISOQUINE; DEXTROMETHORPHAN; FLUOXETINE; FLUVOXAMINE; GENOMIC DNA; HALOPERIDOL; MAPROTILINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SPARTEINE; TETRACYCLIC ANTIDEPRESSANT AGENT; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; AKATHISIA; ALLELE; DROWSINESS; DRUG INDUCED DISEASE; DRUG METABOLISM; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PARKINSONISM; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PSYCHOPHARMACOTHERAPY; REVIEW;

EID: 0035725185     PISSN: 00315362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in white population
2. Consensus conference on pharmacogenetics, Brussels, Belgium
3. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
4. Extrapyramidal symptoms with selective serotonin reuptake inhibitors
5. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
6. GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin
7. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry
8. The role of individual human cytochrome P450 in drug metabolism and clinical response
9. Fluoxetine and extrapyramidal side effects
10. Genetically variable metabolism of antidepressants and neuroleptic drugs in man
11. Ultrarapid hydroxylation of debrisoquine in Swedish population. Analysis of the molecular genetic basis
12. The genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (P450IID6) phenotypes
13. CYP2D6 multiallelism
14. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital
15. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/spartein genetic polymorphism
16. Determination of Dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection
17. Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs
18. Adverse effects of psychotrophic drugs
19. Rapid detection of the CYP2D6z.ast;3, CYPP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
20. A rapid method for the purification of DNA from blood
21. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthioxol
22. PCR-based genotyping for duplicated and deleted CYP2D6 genes
23. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and pseudogene
24. Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency
25. The UKU Side Effect Rating Scale
26. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents
27. Antidepressants and drug- metabolizing enzymes - Expert group report
28. A simple salting out procedure for extracting DNA from human nucleated cell
29. Newer antidepressants and the cytochrome P450 system
30. 3H] GBR-12935 binding proteins
31. Pharmacogenetics of neuroleptics in the elderly
32. The impact of genetic polymorphisms in risk assessment of drugs
33. Cytochrome P450 2D6 variants in a Caucasian population. Allele frequencies and phenotypic consequences
34. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
35. Debrisoquine oxidation in an Italian population: A study in healthy subjects and in shizophrenic patient
36. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects
37. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study
38. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology
39. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication
40. Rapid detection of CYP2D6 null alleles by long distance and multiplex-polymerase chain reaction
41. Genotyping in patients on psychoactive drug therapy
42. CYP2D6 P M hypothesis of antidepressant extrapyramidal side effects
43. Tricyclic antidepressant-induced extrapyramidal side effects
44. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes